Table 4 Studies of DPP-4 inhibitors to treat nonalcoholic fatty liver disease
From: Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
Author, year country trial name (quality rating) | Population demographics | Interventions (group sizes) duration | Efficacy/effectiveness outcomes A vs. B | Harms A vs. B |
|---|---|---|---|---|
Deng, 2017 [7] China (good) | Patients with type 2 diabetes for less than 2 years without complications and fatty liver diagnosed by ultrasound Age: 64 Sex: 75% male Ethnicity: Liver status: ALT 35 IU/mL; AST: 32 IU/mL BMI: 24 Diabetes: HbA1c 7.4% | A. Sitagliptin 50 to 100 mg (36) B. Diet and exercise Duration: 52 weeks | No difference in change in AST (P = 0.99) or ALT (P = 0.97) between treatment with sitagliptin vs. diet and exercise Greater decrease in HbA1c with sitagliptin (− 0.81) vs. diet and exercise (− 0.25), P < 0.01 at 52 weeks (also at 13, 26, and 39 weeks) | NR |